查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1949606

非小細胞肺癌市場 - 全球產業規模、佔有率、趨勢、機會及預測（按類型、療法、藥物類別、最終用戶、地區和競爭格局分類，2021-2031年）

Non-Small Cell Lung Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Treatment, By Drug Class, By End-User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球非小細胞肺癌市場預計將從 2025 年的 200.2 億美元成長到 2031 年的 368.6 億美元，複合年成長率為 10.71%。

該市場涵蓋治療性介入技術的研發和商業化，例如手術、放射線治療、化療和標靶免疫療法，旨在治療最常見的肺癌類型。推動市場成長的關鍵因素包括全球人口快速老化以及持續存在的呼吸系統風險因素，例如吸菸和環境污染。此外，針對特定基因突變的精準藥物獲得快速監管核准，顯著增加了可治療患者的數量，從而提升了行業收入。

市場概覽
預測期 2027-2031
市場規模：2025年 200.2億美元
市場規模：2031年 368.6億美元
複合年成長率：2026-2031年 10.71%
成長最快的細分市場 放射治療
最大的市場 北美洲

根據世界衛生組織（世衛組織）的數據，肺癌仍將是全球癌症相關死亡的主要原因，也是最常見的惡性腫瘤，預計2024年新增病例將達到約250萬例。儘管臨床需求龐大，但由於先進的生物製劑和標靶治療價格高昂，市場面臨許多障礙。高昂的價格往往導致嚴格的報銷政策，並限制了開發中國家的用藥途徑，從而限制了製藥公司的獲利潛力。

市場促進因素

免疫療法和標靶治療的快速發展正在改變整個產業的臨床療效和收入模式。製藥公司正優先推出抑制特定分子路徑（例如EGFR突變和PD-L1表達）的藥物，從而將標準治療方案從廣譜化療轉向精準腫瘤學。這種向精準腫瘤學的轉變使得高價策略和更長的療程成為可能，直接提升了產業價值。例如，Astra Zeneca在2024年2月的財務報告中宣布，其標靶肺癌藥物泰瑞沙（Tagrisso）的收入成長了9%，達到58億美元，這充分展現了特異性抑制劑市場的商業性實力。

此外，人口老化和環境因素導致惡性腫瘤發生率持續高漲，預計將推動對這些先進治療方法的持續需求。儘管採取了預防措施，新增病例數量龐大，仍需要持續的診斷和治療資源。美國癌症協會預測，2024年1月美國將新增約234,580例肺癌和支氣管癌病例，凸顯了普及治療方法的緊迫性。為了充分利用不斷成長的患者群體，主要企業正在積極進行策略性收購。例如，百時美施貴寶公司於2024年以48億美元的股票價值完成了對Mirati Therapeutics的收購，旨在透過引入新型肺癌治療產品來豐富其癌症治療產品組合。

市場挑戰

新型生物製藥和標靶治療的高昂成本是全球非小細胞肺癌市場成長的主要障礙。治療費用往往超出醫療支付者和患者的負擔能力，尤其是在經濟資源有限的地區。這種差距迫使保險公司實施嚴格的報銷政策，從而限制了病患獲得先進醫療服務的機會。因此，製藥公司面臨市場滲透率低、產生收入受限的困境，因為很大一部分目標族群無法獲得這些必要的治療。

這種可近性差距直接影響產業績效，導致潛在患者群體獲得的治療設備數量減少。當經濟障礙阻礙治療啟動時，市場實際上會萎縮。根據美國肺臟協會統計，2024年美國確診的肺癌患者中，約有20.9%無法接受治療。這項數據表明，由於經濟負擔和保險覆蓋範圍的限制，大量患者群體未能被市場覆蓋，導致臨床需求無法轉化為商業交易，阻礙了整體經濟成長。

市場趨勢

在輔助性治療和輔助性治療中採用免疫療法的策略轉變正在重塑市場動態，使高價值療法得以在疾病早期階段應用。臨床醫生擴大使用免疫查核點抑制劑來預防可切除腫瘤的復發，從而擴大了目標患者群體，並使治療範圍超越了轉移性病例。這種發展趨勢使製造商能夠從轉移前患者身上創造價值，顯著提高收入潛力。例如，默克公司報告稱，截至2024年10月，Keytruda的全球銷售額成長了21%，達到74億美元，並將這一成長歸功於其在早期適應症（尤其是可切除的非小細胞肺癌）中應用的不斷廣泛。

同時，針對HER2和TROP2標記的抗體藥物複合體（ADC）的快速崛起，正為抗藥性腫瘤的治療樹立新的標準。這些先進的生物製藥可將細胞毒性藥物直接遞送至癌細胞，並日益取代傳統化療，用於治療初始標靶治療後病情進展的患者。隨著療效數據的累積和符合監管核准的患者群體不斷擴大，該領域正經歷爆炸式的商業性化應用。根據Astra Zeneca截至2024年11月的會計年度數據，其針對HER2的ADC藥物Enhertu在前九個月的全球年銷售額達到27億美元，顯示這種創新療法正迅速滲透市場。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球非小細胞肺癌市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（腺癌、鱗狀細胞癌、大細胞癌）
    • 治療方法（化療、免疫療法、放射線治療、手術、標靶治療）
    • 依藥物類別（血管新生抑制劑、表皮生長因子受體阻斷劑、激酶抑制劑、微管穩定劑、抗葉酸劑、PD-1/PD-L1抑制劑）
    • 依最終使用者（醫院、診所、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美非小細胞肺癌市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲非小細胞肺癌市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區非小細胞肺癌市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲非小細胞肺癌市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲非小細胞肺癌市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球非小細胞肺癌市場：SWOT分析

第14章 波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Bayar Healthcare AG
  • Eli Lilly & Co.
  • Biogen Inc
  • Merck & Co
  • AbbVie Inc
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc
  • Avid Bioservices Inc
  • Blueprint Medicines Company

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17497

The Global Non-Small Cell Lung Cancer Market is projected to expand from USD 20.02 Billion in 2025 to USD 36.86 Billion by 2031, reflecting a CAGR of 10.71%. This market encompasses the development and commercialization of therapeutic interventions, such as surgery, radiation, chemotherapy, and targeted immunotherapies, specifically aimed at treating the most common form of lung cancer. Key factors propelling growth include a rapidly aging global population and the persistence of respiratory risk factors like smoking and environmental pollution. Additionally, the expedited regulatory approval of precision medicines targeting specific genetic mutations is notably increasing the number of treatable patients and bolstering industry revenues.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 20.02 Billion
Market Size 2031USD 36.86 Billion
CAGR 2026-203110.71%
Fastest Growing SegmentRadiation Therapy
Largest MarketNorth America

According to the World Health Organization, lung cancer remained the leading cause of cancer-related mortality and the most frequently diagnosed malignancy globally in 2024, with approximately 2.5 million new cases. Despite this massive clinical demand, the market faces significant hurdles due to the high costs associated with advanced biologic and targeted therapies. These expensive price points often lead to strict reimbursement policies and restricted access in developing nations, limiting the revenue potential for pharmaceutical manufacturers.

Market Driver

The rapid evolution of immunotherapy and targeted therapeutics is transforming clinical results and revenue models within the industry. Pharmaceutical developers are prioritizing the launch of agents that block specific molecular pathways, such as EGFR mutations and PD-L1 expressions, shifting the standard of care away from broad-spectrum chemotherapy. This move toward precision oncology enables premium pricing strategies and longer treatment durations, which directly enhance industry value. For instance, AstraZeneca reported in its February 2024 results that revenue for the targeted lung cancer therapy Tagrisso rose by 9% to $5.8 billion, demonstrating the significant commercial strength of specialized inhibitors globally.

Furthermore, the persistently high rates of malignant neoplasms, fueled by aging populations and environmental exposure, ensure a steady demand for these advanced interventions. Despite prevention efforts, the sheer volume of new cases requires continuous diagnostic and therapeutic resources. The American Cancer Society projected in January 2024 that approximately 234,580 new lung and bronchus cancer cases would be diagnosed in the United States, highlighting the urgent need for accessible treatments. To leverage this growing patient base, major companies are pursuing strategic acquisitions; for example, Bristol Myers Squibb finalized the acquisition of Mirati Therapeutics in 2024 for an equity value of $4.8 billion to diversify its oncology portfolio with new lung cancer assets.

Market Challenge

The substantial expense linked to new biologic and targeted therapies represents a major obstacle to the growth of the Global Non-Small Cell Lung Cancer Market. High treatment costs often surpass the financial limits of healthcare payers and patients, particularly in areas with constrained economic resources. This disparity compels insurance providers to implement rigorous reimbursement policies, thereby limiting patient access to advanced care. As a result, pharmaceutical manufacturers encounter reduced market penetration because a large portion of the eligible population cannot afford these essential treatments, creating a bottleneck in revenue generation.

This gap in accessibility directly affects industry performance by lowering the volume of therapeutic units sold to the potential patient pool. When financial hurdles prevent the initiation of treatment, the market effectively shrinks. According to the American Lung Association, approximately 20.9% of diagnosed lung cancer cases in the United States received no treatment in 2024. This statistic highlights a significant portion of the patient population that remains uncaptured by the market, largely due to affordability issues and coverage restrictions, preventing the conversion of clinical demand into commercial transactions and hindering overall financial growth.

Market Trends

A strategic shift involving the use of immunotherapy regimens in neoadjuvant and adjuvant settings is reshaping market dynamics by introducing high-value treatments at earlier disease stages. Clinicians are increasingly utilizing immune checkpoint inhibitors for resectable tumors to prevent recurrence, which broadens the addressable patient base and extends treatment beyond metastatic cases. This evolution enables manufacturers to generate value from patients prior to metastasis, significantly boosting revenue potential. For example, Merck & Co., Inc. reported in October 2024 that global sales of Keytruda increased by 21% to $7.4 billion, a rise explicitly attributed to greater adoption in earlier-stage indications, specifically resectable non-small cell lung cancer.

Simultaneously, the rapid rise of Antibody-Drug Conjugates (ADCs) targeting HER2 and TROP2 markers is establishing a new standard of care for resistant tumors. These sophisticated biologics deliver cytotoxic agents directly to cancer cells, displacing traditional chemotherapy in various treatment lines for patients who progress after initial targeted therapies. This segment is witnessing explosive commercial adoption as efficacy data matures and regulatory approvals cover wider patient groups. According to AstraZeneca's November 2024 results, combined global sales of the HER2-directed ADC Enhertu reached $2.7 billion in the first nine months of the year, highlighting the swift market penetration of this innovative therapeutic approach.

Key Market Players

  • Bayar Healthcare AG
  • Eli Lilly & Co.
  • Biogen Inc
  • Merck & Co
  • AbbVie Inc
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc
  • Avid Bioservices Inc
  • Blueprint Medicines Company

Report Scope

In this report, the Global Non-Small Cell Lung Cancer Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-Small Cell Lung Cancer Market, By Type

  • Adenocarcinoma
  • Squamous Cell Carcinoma
  • Large Cell Carcinoma

Non-Small Cell Lung Cancer Market, By Treatment

  • Chemotherapy
  • Immunotherapy
  • Radiation Therapy
  • Surgery
  • Targeted Therapy Drugs

Non-Small Cell Lung Cancer Market, By Drug Class

  • Angiogenesis Inhibitor
  • Epidermal Growth Factor Receptor Blocker
  • Kinase Inhibitor
  • Microtubule Stabilizer
  • Folate Antimetabolites
  • PD-1/ PD-L1 Inhibitor

Non-Small Cell Lung Cancer Market, By End-User

  • Hospitals & Clinics
  • Others

Non-Small Cell Lung Cancer Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Non-Small Cell Lung Cancer Market.

Available Customizations:

Global Non-Small Cell Lung Cancer Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Non-Small Cell Lung Cancer Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma)
    • 5.2.2. By Treatment (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, Targeted Therapy Drugs)
    • 5.2.3. By Drug Class (Angiogenesis Inhibitor, Epidermal Growth Factor Receptor Blocker, Kinase Inhibitor, Microtubule Stabilizer, Folate Antimetabolites, PD-1/ PD-L1 Inhibitor)
    • 5.2.4. By End-User (Hospitals & Clinics, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Non-Small Cell Lung Cancer Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Treatment
    • 6.2.3. By Drug Class
    • 6.2.4. By End-User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Non-Small Cell Lung Cancer Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Treatment
        • 6.3.1.2.3. By Drug Class
        • 6.3.1.2.4. By End-User
    • 6.3.2. Canada Non-Small Cell Lung Cancer Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Treatment
        • 6.3.2.2.3. By Drug Class
        • 6.3.2.2.4. By End-User
    • 6.3.3. Mexico Non-Small Cell Lung Cancer Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Treatment
        • 6.3.3.2.3. By Drug Class
        • 6.3.3.2.4. By End-User

7. Europe Non-Small Cell Lung Cancer Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Treatment
    • 7.2.3. By Drug Class
    • 7.2.4. By End-User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Non-Small Cell Lung Cancer Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Treatment
        • 7.3.1.2.3. By Drug Class
        • 7.3.1.2.4. By End-User
    • 7.3.2. France Non-Small Cell Lung Cancer Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Treatment
        • 7.3.2.2.3. By Drug Class
        • 7.3.2.2.4. By End-User
    • 7.3.3. United Kingdom Non-Small Cell Lung Cancer Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Treatment
        • 7.3.3.2.3. By Drug Class
        • 7.3.3.2.4. By End-User
    • 7.3.4. Italy Non-Small Cell Lung Cancer Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Treatment
        • 7.3.4.2.3. By Drug Class
        • 7.3.4.2.4. By End-User
    • 7.3.5. Spain Non-Small Cell Lung Cancer Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Treatment
        • 7.3.5.2.3. By Drug Class
        • 7.3.5.2.4. By End-User

8. Asia Pacific Non-Small Cell Lung Cancer Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Treatment
    • 8.2.3. By Drug Class
    • 8.2.4. By End-User
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Non-Small Cell Lung Cancer Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Treatment
        • 8.3.1.2.3. By Drug Class
        • 8.3.1.2.4. By End-User
    • 8.3.2. India Non-Small Cell Lung Cancer Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Treatment
        • 8.3.2.2.3. By Drug Class
        • 8.3.2.2.4. By End-User
    • 8.3.3. Japan Non-Small Cell Lung Cancer Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Treatment
        • 8.3.3.2.3. By Drug Class
        • 8.3.3.2.4. By End-User
    • 8.3.4. South Korea Non-Small Cell Lung Cancer Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Treatment
        • 8.3.4.2.3. By Drug Class
        • 8.3.4.2.4. By End-User
    • 8.3.5. Australia Non-Small Cell Lung Cancer Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Treatment
        • 8.3.5.2.3. By Drug Class
        • 8.3.5.2.4. By End-User

9. Middle East & Africa Non-Small Cell Lung Cancer Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Treatment
    • 9.2.3. By Drug Class
    • 9.2.4. By End-User
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Non-Small Cell Lung Cancer Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Treatment
        • 9.3.1.2.3. By Drug Class
        • 9.3.1.2.4. By End-User
    • 9.3.2. UAE Non-Small Cell Lung Cancer Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Treatment
        • 9.3.2.2.3. By Drug Class
        • 9.3.2.2.4. By End-User
    • 9.3.3. South Africa Non-Small Cell Lung Cancer Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Treatment
        • 9.3.3.2.3. By Drug Class
        • 9.3.3.2.4. By End-User

10. South America Non-Small Cell Lung Cancer Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Treatment
    • 10.2.3. By Drug Class
    • 10.2.4. By End-User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Non-Small Cell Lung Cancer Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Treatment
        • 10.3.1.2.3. By Drug Class
        • 10.3.1.2.4. By End-User
    • 10.3.2. Colombia Non-Small Cell Lung Cancer Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Treatment
        • 10.3.2.2.3. By Drug Class
        • 10.3.2.2.4. By End-User
    • 10.3.3. Argentina Non-Small Cell Lung Cancer Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Treatment
        • 10.3.3.2.3. By Drug Class
        • 10.3.3.2.4. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Non-Small Cell Lung Cancer Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Bayar Healthcare AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Eli Lilly & Co.
  • 15.3. Biogen Inc
  • 15.4. Merck & Co
  • 15.5. AbbVie Inc
  • 15.6. AstraZeneca PLC
  • 15.7. Novartis AG
  • 15.8. Pfizer Inc
  • 15.9. Avid Bioservices Inc
  • 15.10. Blueprint Medicines Company

16. Strategic Recommendations

17. About Us & Disclaimer